Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24106783 | 0.83 | ALDH1A1 (0.55) | NPC1RAB9ASMN1; SMN2TP53PTPRC | |
| SCHEMBL6048312 | 0.83 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL1772629 | 0.82 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL294721 | 0.82 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2TP53PTPRC | |
| SCHEMBL30136447 | 0.82 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2TP53PTPRC | |
| SCHEMBL12686368 | 0.81 | TP53 (0.52) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL27669651 | 0.81 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HSD17B10TP53 | |
| SCHEMBL1704521 | 0.81 | ABL1 (0.62) | SMN1; SMN2PTPRCPTPN1XDHAPP | |
| SCHEMBL4425113 | 0.81 | SYK (0.56) | NPC1RAB9ASMN1; SMN2PTPRCPTPN1 | |
| SCHEMBL5690752 | 0.81 | SQOR (0.55) | NPC1RAB9ASMN1; SMN2TP53PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109821558-A | A kind of synthetic method for treating breast cancer medicines arzoxifene intermediate | 马建 | 2019-05-31 | — | — | CN | claimed |
| WO-2025028365-A1 | PHOTOCHROMIC COMPOUND, PHENOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | 株式会社トクヤマ | 2025-02-06 | — | — | WO | disclosed |
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| EP-2086995-A1 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064066-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1227086-B1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-6518257-B1 | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-0853618-A4 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5958918-A | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. | 1999-09-28 | — | — | US | disclosed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | OXER1, AK2, GPR119 | NPC1 1434/4885RAB9A 2816/4885SMN1; SMN2 4397/4885 |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | NPC1 3019/4885RAB9A 1540/4885SMN1; SMN2 3930/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | NPC1 3019/4885RAB9A 1540/4885SMN1; SMN2 3930/4885 |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, PYGL | NPC1 167/4885RAB9A 1854/4885SMN1; SMN2 4675/4885 |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | AK2, PRKAA2, PRKAA1 | NPC1 2374/4885RAB9A 2034/4885SMN1; SMN2 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.